JP2013512889A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013512889A5 JP2013512889A5 JP2012541584A JP2012541584A JP2013512889A5 JP 2013512889 A5 JP2013512889 A5 JP 2013512889A5 JP 2012541584 A JP2012541584 A JP 2012541584A JP 2012541584 A JP2012541584 A JP 2012541584A JP 2013512889 A5 JP2013512889 A5 JP 2013512889A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- sheep
- difficile
- toxin
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 27
- 241001494479 Pecora Species 0.000 claims 19
- 239000003053 toxin Substances 0.000 claims 18
- 231100000765 toxin Toxicity 0.000 claims 18
- 108700012359 toxins Proteins 0.000 claims 18
- 238000000034 method Methods 0.000 claims 12
- 102000004142 Trypsin Human genes 0.000 claims 9
- 108090000317 Chymotrypsin Proteins 0.000 claims 8
- 108090000631 Trypsin Proteins 0.000 claims 8
- 229960002376 chymotrypsin Drugs 0.000 claims 8
- 230000003053 immunization Effects 0.000 claims 8
- 238000002649 immunization Methods 0.000 claims 8
- 239000008194 pharmaceutical composition Substances 0.000 claims 8
- 239000012588 trypsin Substances 0.000 claims 8
- 208000015181 infectious disease Diseases 0.000 claims 5
- 101000963974 Hydrophis stokesii Alpha-elapitoxin-Ast2b Proteins 0.000 claims 4
- 101000964025 Naja naja Long neurotoxin 3 Proteins 0.000 claims 4
- 101710084578 Short neurotoxin 1 Proteins 0.000 claims 4
- 101710182223 Toxin B Proteins 0.000 claims 4
- 101710182532 Toxin a Proteins 0.000 claims 4
- 230000002265 prevention Effects 0.000 claims 4
- 239000000243 solution Substances 0.000 claims 4
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical class [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims 3
- 241000193163 Clostridioides difficile Species 0.000 claims 3
- 229940069428 antacid Drugs 0.000 claims 3
- 239000003159 antacid agent Substances 0.000 claims 3
- 230000001458 anti-acid effect Effects 0.000 claims 3
- 208000028235 central diabetes insipidus Diseases 0.000 claims 3
- 230000002163 immunogen Effects 0.000 claims 3
- 108091005804 Peptidases Proteins 0.000 claims 2
- 239000004365 Protease Substances 0.000 claims 2
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims 2
- 239000002671 adjuvant Substances 0.000 claims 2
- 239000000427 antigen Substances 0.000 claims 2
- 108091007433 antigens Proteins 0.000 claims 2
- 102000036639 antigens Human genes 0.000 claims 2
- 239000007853 buffer solution Substances 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 239000012634 fragment Substances 0.000 claims 2
- 210000004211 gastric acid Anatomy 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 238000007911 parenteral administration Methods 0.000 claims 2
- 230000002797 proteolythic effect Effects 0.000 claims 2
- 230000009885 systemic effect Effects 0.000 claims 2
- 229940122644 Chymotrypsin inhibitor Drugs 0.000 claims 1
- 101710137926 Chymotrypsin inhibitor Proteins 0.000 claims 1
- 229940122618 Trypsin inhibitor Drugs 0.000 claims 1
- 101710162629 Trypsin inhibitor Proteins 0.000 claims 1
- 239000003242 anti bacterial agent Substances 0.000 claims 1
- 229940088710 antibiotic agent Drugs 0.000 claims 1
- 239000007864 aqueous solution Substances 0.000 claims 1
- 239000011324 bead Substances 0.000 claims 1
- 239000003541 chymotrypsin inhibitor Substances 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- -1 granular matrices Substances 0.000 claims 1
- 230000016784 immunoglobulin production Effects 0.000 claims 1
- 239000002502 liposome Substances 0.000 claims 1
- 210000001589 microsome Anatomy 0.000 claims 1
- 239000004005 microsphere Substances 0.000 claims 1
- 239000002105 nanoparticle Substances 0.000 claims 1
- 239000008188 pellet Substances 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 230000000306 recurrent effect Effects 0.000 claims 1
- 239000002753 trypsin inhibitor Substances 0.000 claims 1
- 210000001364 upper extremity Anatomy 0.000 claims 1
- 239000003981 vehicle Substances 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0921288.7A GB0921288D0 (en) | 2009-12-04 | 2009-12-04 | Therapies for preventing or suppressing clostridium difficile infection |
| GB0921288.7 | 2009-12-04 | ||
| PCT/GB2010/050288 WO2010094970A1 (en) | 2009-02-20 | 2010-02-19 | Antibodies to clostridium difficile toxins |
| GBPCT/GB2010/050288 | 2010-02-19 | ||
| PCT/GB2010/052035 WO2011067616A1 (en) | 2009-12-04 | 2010-12-06 | Therapies for preventing or suppressing clostridium difficile infection |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013512889A JP2013512889A (ja) | 2013-04-18 |
| JP2013512889A5 true JP2013512889A5 (enExample) | 2014-01-30 |
| JP5877161B2 JP5877161B2 (ja) | 2016-03-02 |
Family
ID=41641956
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012541584A Active JP5877161B2 (ja) | 2009-12-04 | 2010-12-06 | クロストリジウム・ディフィシル感染を予防または抑制するための治療法 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US8921529B2 (enExample) |
| EP (1) | EP2506877B1 (enExample) |
| JP (1) | JP5877161B2 (enExample) |
| CN (1) | CN102740889A (enExample) |
| BR (1) | BR112012013496A2 (enExample) |
| CA (1) | CA2782639C (enExample) |
| GB (1) | GB0921288D0 (enExample) |
| MY (1) | MY158712A (enExample) |
| SG (1) | SG181127A1 (enExample) |
| WO (1) | WO2011067616A1 (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5740714B2 (ja) | 2009-02-20 | 2015-06-24 | ヘルス プロテクション エージェンシー | クロストリジウム・ディフィシル（Ｃｌｏｓｔｒｉｄｉｕｍｄｉｆｆｉｃｉｌｅ）毒素に対する抗体 |
| GB0921288D0 (en) | 2009-12-04 | 2010-01-20 | Health Prot Agency | Therapies for preventing or suppressing clostridium difficile infection |
| CN103957931B (zh) * | 2010-09-03 | 2017-10-24 | 瓦尔内瓦奥地利有限责任公司 | 艰难梭状芽胞杆菌毒素a和毒素b蛋白的分离多肽及其用途 |
| GB201016742D0 (en) | 2010-10-05 | 2010-11-17 | Health Prot Agency | Clostridium difficile antigens |
| SI3505531T1 (sl) | 2011-04-22 | 2024-02-29 | Wyeth Llc | Kompozicije, povezane z mutantnim toksinom clostridium difficile in njegovimii metodami |
| CA2845884A1 (en) | 2011-08-22 | 2013-02-28 | Cangene Corporation | Clostridium difficile antibodies |
| MX2014006630A (es) | 2011-12-08 | 2014-07-09 | Novartis Ag | Vacuna a base toxina clostridium difficile. |
| DE102011121237A1 (de) * | 2011-12-14 | 2013-06-20 | Universitätsklinikum Hamburg-Eppendorf | Einzeldomänen-Antikörper gegen Clostridium difficile Toxin CDTa |
| AR089797A1 (es) * | 2012-01-27 | 2014-09-17 | Merck Sharp & Dohme | Vacunas contra clostridum difficile que comprenden toxinas recombinantes |
| BR122016023101B1 (pt) | 2012-10-21 | 2022-03-22 | Pfizer Inc | Polipeptídeo, composição imunogênica que o compreende, bem como célula recombinante derivada de clostridium difficile |
| US20160002278A1 (en) | 2013-03-08 | 2016-01-07 | Cipla Limited | Pharmaceutical Compositions for Rectal Administration |
| CN105308066A (zh) * | 2013-03-15 | 2016-02-03 | 圣诺菲·帕斯图尔公司 | 类毒素、组合物和相关的方法 |
| US10226523B2 (en) * | 2013-04-22 | 2019-03-12 | The Board Of Regents Of The University Of Oklahoma | Clostridium difficile vaccine and methods of use |
| MX2015017257A (es) | 2013-06-14 | 2016-11-11 | Sanofi Pasteur Inc | Composiciones y metodos de inmunizar contra clostridium difficile. |
| EP2957570B1 (en) * | 2014-06-20 | 2019-04-17 | Immunimed Inc. | Polyclonal antibodies against clostridium difficile and uses thereof |
| US10513552B2 (en) | 2014-06-20 | 2019-12-24 | Immunimed Inc. | Use of polyclonal antibodies against clostridium difficile for treatment of inflammatory bowel disease |
| CA2954087C (en) * | 2014-07-25 | 2023-09-19 | Biosynth S.R.L. | Glycoconjugate vaccines comprising basic units of a molecular construct expressing built-in multiple epitopes for the formulation of a broad-spectrum vaccine against infections due to enteropathogenic bacteria |
| EP3121272A1 (en) * | 2015-07-24 | 2017-01-25 | Zymetech ehf. | Novel fish trypsin isoforms and their use |
| WO2017173068A1 (en) * | 2016-03-30 | 2017-10-05 | University Of Maryland, Baltimore | Microparticulate system for colonic drug delivery |
| GB201701404D0 (en) | 2017-01-27 | 2017-03-15 | Micropharm Ltd | Therapies for treating inflammatory disorders |
| GB202019817D0 (en) * | 2020-12-15 | 2021-01-27 | Univ Oxford Innovation Ltd | Ligand-binding polypeptides and uses thereof |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS608225A (ja) | 1983-06-29 | 1985-01-17 | Kowa Co | 腸管吸収医薬組成物 |
| US5601823A (en) * | 1989-10-31 | 1997-02-11 | Ophidian Pharmaceuticals, Inc. | Avian antitoxins to clostridium difficle toxin A |
| CA2197714A1 (en) | 1994-09-06 | 1996-03-14 | Immucell Corporation | Therapeutic treatment of clostridium difficile associated diseases |
| EP1041149B8 (en) * | 1994-10-24 | 2007-10-03 | Allergan, Inc. | Vaccine and antitoxin for treatment and prevention of C. difficile disease |
| US6096310A (en) | 1997-04-15 | 2000-08-01 | Bier; Milan | Oral immunotherapy of bacterial overgrowth |
| AU746859B2 (en) | 1997-06-20 | 2002-05-02 | Imperial College Of Science, Technology And Medicine | Immonogenic fragments of toxin a of clostridium difficile |
| US6214341B1 (en) | 1997-10-20 | 2001-04-10 | Oravax | Passive immunization against Clostridium difficile disease |
| US6969520B2 (en) | 1997-10-20 | 2005-11-29 | Acambis Inc. | Active immunization against clostridium difficile disease |
| US6074689A (en) | 1998-03-10 | 2000-06-13 | Immucell Corporation | Colonic delivery of protein or peptide compositions |
| US20020009429A1 (en) | 1999-01-29 | 2002-01-24 | Galagen, Inc. | Pharmaceutical composition comprising a selected antigen and candida species antigen and methods |
| US6673574B2 (en) | 2000-11-30 | 2004-01-06 | Unigene Laboratories Inc. | Oral delivery of peptides using enzyme-cleavable membrane translocators |
| GB0205206D0 (en) | 2002-03-06 | 2002-04-17 | Oxoid Ltd | Synthetic peptides |
| AU2003299527A1 (en) | 2002-06-17 | 2004-06-07 | Jimmy D. Ballard | Mutant of clostridium difficile toxin b and methods of use |
| AU2003279750A1 (en) * | 2002-06-28 | 2004-01-19 | Nastech Pharmaceutical Company Inc. | Compositions and methods for modulating physiology of epithelial junctional adhesion molecules for enhanced mucosal delivery of therapeutic compounds |
| GB0309126D0 (en) | 2003-04-17 | 2003-05-28 | Neutec Pharma Plc | Clostridium difficile focussed antibodies |
| SI2857418T1 (en) * | 2004-02-06 | 2018-01-31 | University Of Massachusetts | Antibodies against Clostridium difficile toxins and uses thereof |
| WO2005110465A2 (en) * | 2004-04-29 | 2005-11-24 | Glaxosmithkline Istrazivacki Centar Zagreb D.O.O. | Oral formulations comprising bone morphogenetic proteins for treating metabolic bone diseases |
| US20090087478A1 (en) | 2004-12-27 | 2009-04-02 | Progenics Pharmaceuticals (Nevada), Inc. | Orally Deliverable and Anti-Toxin Antibodies and Methods for Making and Using Them |
| US7794721B2 (en) | 2006-12-13 | 2010-09-14 | Simon Michael R | Synthesis of human secretory IgM and the treatment of clostridium difficile associated diseases herewith |
| CN101363867B (zh) | 2008-05-26 | 2012-12-19 | 北京庄笛浩禾生物医学科技有限公司 | 一种艰难梭菌a、b毒素胶体金检测试纸条及其制备方法 |
| JP5740714B2 (ja) | 2009-02-20 | 2015-06-24 | ヘルス プロテクション エージェンシー | クロストリジウム・ディフィシル（Ｃｌｏｓｔｒｉｄｉｕｍｄｉｆｆｉｃｉｌｅ）毒素に対する抗体 |
| GB0921288D0 (en) | 2009-12-04 | 2010-01-20 | Health Prot Agency | Therapies for preventing or suppressing clostridium difficile infection |
-
2009
- 2009-12-04 GB GBGB0921288.7A patent/GB0921288D0/en not_active Ceased
-
2010
- 2010-12-06 CA CA2782639A patent/CA2782639C/en active Active
- 2010-12-06 BR BR112012013496A patent/BR112012013496A2/pt not_active IP Right Cessation
- 2010-12-06 WO PCT/GB2010/052035 patent/WO2011067616A1/en not_active Ceased
- 2010-12-06 EP EP10787170.9A patent/EP2506877B1/en active Active
- 2010-12-06 CN CN2010800537789A patent/CN102740889A/zh active Pending
- 2010-12-06 US US13/513,555 patent/US8921529B2/en active Active
- 2010-12-06 SG SG2012039616A patent/SG181127A1/en unknown
- 2010-12-06 JP JP2012541584A patent/JP5877161B2/ja active Active
- 2010-12-06 MY MYPI2012002466A patent/MY158712A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013512889A5 (enExample) | ||
| O'Brien-Simpson et al. | RgpA-Kgp peptide-based immunogens provide protection against Porphyromonas gingivalis challenge in a murine lesion model | |
| JP2012504660A5 (enExample) | ||
| ES2618605T3 (es) | Oligopéptidos de metaloproteinasas y su uso terapéutico | |
| JP2009520758A5 (enExample) | ||
| JP5661744B2 (ja) | 腸球菌由来のポリペプチド、及びワクチン接種のためのその使用 | |
| Liu et al. | Immunological characterisation and immunoprotective efficacy of functional domain antigens of botulinum neurotoxin serotype A | |
| AU2014257172B2 (en) | Clostridium difficile vaccine and methods of use | |
| CA2790219C (en) | Treatment or prevention of infection | |
| EP3383884A1 (en) | Method for preventing or treating nosocomial pneumonia | |
| JP2017160238A (ja) | ストレプトコッカス・ニューモニエ（Ｓｔｒｅｐｔｏｃｏｃｃｕｓ ｐｎｅｕｍｏｎｉａｅ）に対する融合抗原ワクチンおよび組成物 | |
| CN1437482A (zh) | 用于治疗变态反应的重组的或纯化的多克隆抗体 | |
| WO2007145760A3 (en) | Anthrax compositions and methods of use and production | |
| JP2015513314A5 (enExample) | ||
| ES2551699T3 (es) | Composiciones, procedimientos y kits | |
| CN116406274A (zh) | 用于治疗冠状病毒的cd3抗体 | |
| WO2014144222A2 (en) | Compositions and methods of treating fungal and bacterial pathogens | |
| Tsurumi et al. | Production of antibody against a synthetic peptide of Porphyromonas gingivalis 40-kDa outer membrane protein | |
| JP2006500386A (ja) | ペスト菌ｆ１抗原に特異的な抗体とペスト菌ｖ抗原に特異的な抗体のうちの１又は２種の抗体を含む抗エルシニアワクチン | |
| Kim et al. | Development of an equine antitoxin by immunizing the Halla Horse with the receptor-binding domain of botulinum neurotoxin type A1 | |
| WO2024229199A2 (en) | Humoral modulation in vaccinated and virally infected subjects with granulocyte-macrophage colony-stimulating factor (gm-csf) | |
| JP7439371B2 (ja) | Ｃａｎｄｉｄａ ａｕｒｉｓ感染症の治療方法 | |
| WO2022253193A1 (zh) | 一种新型冠状病毒疫苗多肽及其纳米乳制剂在预防新冠野毒株和突变株感染中的应用 | |
| EP2915543A1 (en) | Polypeptides derived from Enterococcus and their use for vaccination and the generation of therapeutic antibodies | |
| Lepletier et al. | Sub-clinical exposure to Streptococcus pyogenes drives the development of immunity |